Since the STING pathway activates innate antitumor immunity, we assessed if combination therapy can favorably convert “cold,” poorly immunogenic TME into “hot” TME by shifting the tumor-associated macrophage (TAM) phenotype from protumorigenic M2 toward antitumorigenic M1. The gene discussed is STING1; the disease is neoplasm.